Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review

BACKGROUND: Esophageal cancer (EC) is the seventh most common cancer in the world, with 604,000 new cases diagnosed each year. Immune checkpoint inhibitors (ICIs) including programmed death ligand-1 (PD-L1) inhibitors have demonstrated a considerable survival advantage over chemotherapy in numerous...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Kanghao, Chen, Hui, Xu, Congcong, Chen, Dong, Jin, Zixian, Ren, Sijia, Witharana, Pasan, Chen, Baofu, Shen, Jianfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089833/
https://www.ncbi.nlm.nih.gov/pubmed/37065572
http://dx.doi.org/10.21037/jtd-22-1169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089833/
https://www.ncbi.nlm.nih.gov/pubmed/37065572
http://dx.doi.org/10.21037/jtd-22-1169

Ejemplares similares